BridgeMD
Benefits of early discontinuation of antibiotic therapy versus standard management in elderly patients hospitalized for viral infection: a multicenter, open-label, cluster-randomized controlled study
EU CTIS ID: 2024-515695-13-00
What this study is testing
To show that early cessation of antibiotics in viral pneumonia (presumed or confirmed) reduces antibiotic consumption at one month.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patient hospitalized for a lower respiratory infection defined as : o the presence of 2 of the following 4 signs : o hyperthermia >38°C, o hyperleukocytosis ≥12000 or ≤4000, o aspirations/purulent sputum, o rales on pulmonary auscultation indicating parenchymal involvement o associated with a pulmonary image (standard X-ray, CT or ultrasound).
- Microbiological diagnostic sample taken within 48 hours
You likely can't join if
- Planned hospitalization < 48 h or transfer to another center within 7 days
- Patient in septic shock
- Febrile aplasia
- No diagnostic microbiological sample (>48h after admission)
- Moribund patient
- Death expected within a week
See the full eligibility criteria
- Patient hospitalized for a lower respiratory infection defined as : o the presence of 2 of the following 4 signs : o hyperthermia >38°C, o hyperleukocytosis ≥12000 or ≤4000, o aspirations/purulent sputum, o rales on pulmonary auscultation indicating parenchymal involvement o associated with a pulmonary image (standard X-ray, CT or ultrasound).
- Microbiological diagnostic sample taken within 48 hours
- Planned hospitalization < 48 h or transfer to another center within 7 days
- Patient in septic shock
- Febrile aplasia
- No diagnostic microbiological sample (>48h after admission)
- Moribund patient
- Death expected within a week
- Inhalation proven by endoscopy or eyewitness
- Purulent pleurisy, lung abscess, or other concomitant bacterial infection requiring antibiotic therapy.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.